Prescriber Checkup | EMEND

Prescriber Checkup

The Doctors and Drugs in Medicare Part D

EMEND

FOSAPREPITANT DIMEGLUMINE

Emend (aprepitant) blocks substance P from starting the nausea and vomiting response in the brain. Source: Iodine

At a Glance: This Drug in 2015

891
Medicare Part D Claims

Rank: 2166 of 3395

$361K
Retail Cost

Rank: 2041 of 3395

275
Patients

Rank: 2217 of 3395

114
Prescribers

Rank: 2503 of 3395

More info on EMEND »

Information courtesy of

This Drug's History

Claims

The number of Medicare prescriptions for this drug each year

161

2011

333

2012

629

2013

843

2014

891

2015

Spending

The total Part D spending on this drug
each year

$64.8K

2011

$133K

2012

$242K

2013

$332K

2014

$361K

2015

Average Patient Cost

Average amount that patients without a low-income subsidy paid each year.

$99

2011

$131

2012

$91

2013

$104

2014

$120

2015

Use by state

State Patients Claims Cost
New York 113 354 $156K
New Jersey 61 196 $76K
Florida 24 125 $36.1K
California 20 74 $27.6K
Tennessee 35 $18.5K
Maryland 29 $9,714
Massachusetts 21 $7,916
Pennsylvania 11 $5,030
Illinois 11 $7,776
North Carolina 11 $6,345
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. The data for 2015 includes more than 1.4 billion prescriptions written by nearly 1.4 million doctors, nurses and other providers. This database lists about 447,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. More than three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.